Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV-1 | 11 | 2020 | 3365 | 0.92 | Why? |
| HIV Infections | 19 | 2020 | 11620 | 0.80 | Why? |
| HIV | 4 | 2019 | 1116 | 0.69 | Why? |
| Antibody Affinity | 3 | 2020 | 1078 | 0.69 | Why? |
| Hepacivirus | 3 | 2018 | 1509 | 0.69 | Why? |
| Hepatitis C | 3 | 2018 | 1514 | 0.66 | Why? |
| HIV Antigens | 1 | 2017 | 102 | 0.64 | Why? |
| Hepatitis C Antibodies | 1 | 2016 | 120 | 0.59 | Why? |
| Molecular Epidemiology | 1 | 2019 | 1638 | 0.52 | Why? |
| Dried Blood Spot Testing | 1 | 2017 | 383 | 0.51 | Why? |
| Epidemiologic Methods | 1 | 2017 | 392 | 0.50 | Why? |
| HIV Antibodies | 2 | 2017 | 776 | 0.47 | Why? |
| Genotype | 2 | 2019 | 4697 | 0.41 | Why? |
| Herpes Genitalis | 3 | 2018 | 90 | 0.39 | Why? |
| HIV Seropositivity | 3 | 2017 | 320 | 0.38 | Why? |
| Point-of-Care Testing | 1 | 2021 | 2782 | 0.34 | Why? |
| Convalescence | 4 | 2021 | 2829 | 0.32 | Why? |
| Phylogeny | 7 | 2020 | 13341 | 0.31 | Why? |
| Hypoxia | 1 | 2021 | 3626 | 0.31 | Why? |
| Uganda | 6 | 2021 | 1057 | 0.30 | Why? |
| Immunoglobulin G | 6 | 2021 | 21571 | 0.27 | Why? |
| Antibodies, Viral | 12 | 2021 | 51949 | 0.26 | Why? |
| Serologic Tests | 1 | 2017 | 4359 | 0.24 | Why? |
| Disease Transmission, Infectious | 3 | 2019 | 9044 | 0.22 | Why? |
| Viral Load | 10 | 2020 | 15850 | 0.22 | Why? |
| Antibodies, Neutralizing | 6 | 2021 | 25288 | 0.19 | Why? |
| Heterosexuality | 1 | 2019 | 148 | 0.18 | Why? |
| Immunoenzyme Techniques | 1 | 2021 | 448 | 0.18 | Why? |
| Sexual Behavior | 2 | 2018 | 1322 | 0.18 | Why? |
| HIV Integrase Inhibitors | 1 | 2020 | 173 | 0.18 | Why? |
| Human Immunodeficiency Virus Proteins | 1 | 2017 | 20 | 0.18 | Why? |
| Incidence | 8 | 2017 | 25622 | 0.17 | Why? |
| Circumcision, Male | 1 | 2017 | 57 | 0.17 | Why? |
| Hepatitis Antibodies | 1 | 2018 | 100 | 0.17 | Why? |
| Cross Reactions | 4 | 2021 | 4374 | 0.17 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.16 | Why? |
| Zimbabwe | 1 | 2017 | 198 | 0.16 | Why? |
| Endemic Diseases | 2 | 2021 | 480 | 0.16 | Why? |
| Sexual Partners | 2 | 2018 | 612 | 0.16 | Why? |
| Immune Sera | 1 | 2021 | 884 | 0.16 | Why? |
| Executive Function | 1 | 2018 | 173 | 0.16 | Why? |
| Genetic Variation | 3 | 2017 | 3919 | 0.15 | Why? |
| Emergency Service, Hospital | 1 | 2021 | 14232 | 0.15 | Why? |
| Cross-Sectional Studies | 9 | 2021 | 53120 | 0.15 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 386 | 0.15 | Why? |
| Seroconversion | 3 | 2021 | 2515 | 0.15 | Why? |
| Immunoassay | 4 | 2021 | 4485 | 0.15 | Why? |
| Epitope Mapping | 1 | 2020 | 1240 | 0.15 | Why? |
| Models, Immunological | 1 | 2021 | 727 | 0.15 | Why? |
| Models, Genetic | 1 | 2017 | 434 | 0.14 | Why? |
| Coronavirus NL63, Human | 1 | 2020 | 669 | 0.14 | Why? |
| Common Cold | 1 | 2020 | 645 | 0.14 | Why? |
| Hepatitis E virus | 1 | 2018 | 306 | 0.13 | Why? |
| Early Medical Intervention | 1 | 2017 | 487 | 0.13 | Why? |
| AIDS Dementia Complex | 1 | 2014 | 48 | 0.13 | Why? |
| Biomarkers | 3 | 2016 | 23361 | 0.13 | Why? |
| Hepatitis E | 1 | 2018 | 319 | 0.13 | Why? |
| Drug Resistance, Viral | 1 | 2020 | 1083 | 0.12 | Why? |
| Blood Donors | 3 | 2021 | 2956 | 0.12 | Why? |
| Homosexuality, Male | 2 | 2020 | 1158 | 0.12 | Why? |
| Coronavirus OC43, Human | 1 | 2020 | 1157 | 0.12 | Why? |
| Coronavirus 229E, Human | 1 | 2020 | 1241 | 0.12 | Why? |
| ABO Blood-Group System | 1 | 2021 | 995 | 0.11 | Why? |
| Young Adult | 13 | 2021 | 93724 | 0.11 | Why? |
| Cluster Analysis | 2 | 2017 | 3001 | 0.11 | Why? |
| Humans | 39 | 2021 | 930598 | 0.11 | Why? |
| Diagnostic Errors | 1 | 2017 | 865 | 0.11 | Why? |
| Male | 27 | 2021 | 367725 | 0.10 | Why? |
| Acute Disease | 2 | 2021 | 6029 | 0.10 | Why? |
| Female | 27 | 2021 | 380317 | 0.10 | Why? |
| Seroepidemiologic Studies | 3 | 2021 | 10017 | 0.10 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.10 | Why? |
| Receptors, CCR5 | 1 | 2011 | 186 | 0.10 | Why? |
| Adult | 22 | 2021 | 244371 | 0.10 | Why? |
| Diagnostic Tests, Routine | 2 | 2019 | 2643 | 0.10 | Why? |
| HIV Envelope Protein gp120 | 1 | 2011 | 267 | 0.09 | Why? |
| Anti-Retroviral Agents | 1 | 2017 | 1099 | 0.09 | Why? |
| Immune Tolerance | 1 | 2014 | 608 | 0.09 | Why? |
| Cohort Studies | 7 | 2021 | 36005 | 0.09 | Why? |
| Epitopes | 1 | 2020 | 4113 | 0.09 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3633 | 0.08 | Why? |
| Immunity, Cellular | 1 | 2020 | 3614 | 0.08 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.08 | Why? |
| Evolution, Molecular | 2 | 2017 | 3691 | 0.08 | Why? |
| Killer Cells, Natural | 1 | 2017 | 2093 | 0.08 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.08 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2021 | 5837 | 0.08 | Why? |
| Antibody Specificity | 2 | 2021 | 1328 | 0.08 | Why? |
| CD4 Lymphocyte Count | 3 | 2017 | 1517 | 0.08 | Why? |
| African Americans | 1 | 2021 | 3363 | 0.07 | Why? |
| United States | 5 | 2021 | 46150 | 0.07 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2017 | 4545 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.07 | Why? |
| Immunization, Passive | 4 | 2021 | 10067 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| South Africa | 3 | 2018 | 3326 | 0.07 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.06 | Why? |
| HLA Antigens | 2 | 2021 | 830 | 0.06 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.06 | Why? |
| Antibody Formation | 3 | 2021 | 4038 | 0.06 | Why? |
| Schools | 1 | 2018 | 4187 | 0.06 | Why? |
| Hemagglutination | 1 | 2021 | 36 | 0.06 | Why? |
| Biophysical Phenomena | 1 | 2021 | 78 | 0.06 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.06 | Why? |
| Coinfection | 2 | 2018 | 6820 | 0.06 | Why? |
| Hemagglutination Tests | 1 | 2021 | 124 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Disease Progression | 3 | 2014 | 13580 | 0.05 | Why? |
| Phagocytosis | 1 | 2021 | 409 | 0.05 | Why? |
| Aged | 7 | 2021 | 215776 | 0.05 | Why? |
| Antibody-Dependent Cell Cytotoxicity | 1 | 2021 | 349 | 0.05 | Why? |
| Genome, Viral | 2 | 2021 | 13157 | 0.05 | Why? |
| Emtricitabine | 1 | 2020 | 202 | 0.05 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.05 | Why? |
| Bacteria | 1 | 2009 | 1897 | 0.04 | Why? |
| Herpesvirus 2, Human | 1 | 2018 | 137 | 0.04 | Why? |
| Sex Factors | 3 | 2020 | 11014 | 0.04 | Why? |
| Zambia | 1 | 2018 | 401 | 0.04 | Why? |
| Unsafe Sex | 1 | 2018 | 139 | 0.04 | Why? |
| Molecular Diagnostic Techniques | 1 | 2013 | 4239 | 0.04 | Why? |
| Genetic Markers | 1 | 2018 | 318 | 0.04 | Why? |
| Malawi | 1 | 2017 | 287 | 0.04 | Why? |
| Species Specificity | 1 | 2021 | 1356 | 0.04 | Why? |
| Poisson Distribution | 1 | 2017 | 348 | 0.04 | Why? |
| Longitudinal Studies | 3 | 2018 | 9893 | 0.04 | Why? |
| Tenofovir | 1 | 2020 | 449 | 0.04 | Why? |
| Immunodominant Epitopes | 1 | 2021 | 813 | 0.04 | Why? |
| Cameroon | 1 | 2017 | 464 | 0.04 | Why? |
| Virus Replication | 1 | 2017 | 14331 | 0.04 | Why? |
| Blotting, Western | 1 | 2017 | 863 | 0.04 | Why? |
| Public Health Surveillance | 2 | 2019 | 3129 | 0.04 | Why? |
| Transition Temperature | 1 | 2013 | 11 | 0.03 | Why? |
| Complement Activation | 1 | 2021 | 949 | 0.03 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2018 | 782 | 0.03 | Why? |
| Sequence Homology, Amino Acid | 1 | 2017 | 945 | 0.03 | Why? |
| Linear Models | 1 | 2020 | 1914 | 0.03 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.03 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.03 | Why? |
| Cryoelectron Microscopy | 1 | 2020 | 2372 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| RNA, Viral | 2 | 2017 | 32276 | 0.03 | Why? |
| Coronavirus | 1 | 2021 | 18339 | 0.03 | Why? |
| Receptors, CXCR4 | 1 | 2011 | 83 | 0.03 | Why? |
| Hepatitis B, Chronic | 1 | 2018 | 616 | 0.03 | Why? |
| Alleles | 1 | 2017 | 1557 | 0.03 | Why? |
| Immunity, Innate | 1 | 2009 | 6570 | 0.03 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2020 | 1138 | 0.03 | Why? |
| Prospective Studies | 1 | 2016 | 43301 | 0.03 | Why? |
| Bayes Theorem | 1 | 2020 | 3237 | 0.03 | Why? |
| Virulence | 1 | 2017 | 2172 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2020 | 1019 | 0.02 | Why? |
| Protein Conformation | 1 | 2020 | 4386 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.02 | Why? |
| Selection, Genetic | 1 | 2012 | 691 | 0.02 | Why? |
| Biological Transport | 1 | 2009 | 290 | 0.02 | Why? |
| Solubility | 1 | 2009 | 382 | 0.02 | Why? |
| Child | 1 | 2017 | 70012 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Urban Population | 1 | 2018 | 2000 | 0.02 | Why? |
| Point-of-Care Systems | 1 | 2021 | 2955 | 0.02 | Why? |
| Early Diagnosis | 1 | 2016 | 2443 | 0.02 | Why? |
| Residence Characteristics | 1 | 2018 | 1927 | 0.02 | Why? |
| Delivery of Health Care, Integrated | 1 | 2019 | 1549 | 0.02 | Why? |
| Models, Molecular | 1 | 2021 | 7616 | 0.02 | Why? |
| Cytokines | 1 | 2009 | 15010 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Lipopolysaccharide Receptors | 1 | 2009 | 357 | 0.02 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Rural Population | 1 | 2018 | 2408 | 0.02 | Why? |
| Surveys and Questionnaires | 3 | 2018 | 43792 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2017 | 6049 | 0.02 | Why? |
| Lipopolysaccharides | 1 | 2009 | 848 | 0.02 | Why? |
| New York City | 1 | 2018 | 7432 | 0.02 | Why? |
| Host-Pathogen Interactions | 2 | 2017 | 11041 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2012 | 2830 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| India | 1 | 2019 | 11875 | 0.01 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Africa | 1 | 2009 | 2986 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Proportional Hazards Models | 1 | 2011 | 6543 | 0.01 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.01 | Why? |
| Inflammation Mediators | 1 | 2009 | 2654 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2012 | 6740 | 0.01 | Why? |
| Registries | 1 | 2017 | 12327 | 0.01 | Why? |
| Algorithms | 1 | 2013 | 7346 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Animals | 1 | 2020 | 78931 | 0.01 | Why? |
Laeyendecker's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(200)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(193)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_